Sign in
Taking people in United StatesPhase 3

Delaying the Onset of Nearsightedness Until Treatment (DONUT) Clinical Trial

Key facts

Who runs it
Ohio State University
Where
Berkeley, Birmingham, Bloomington, Boston, Chicago, Cleveland, Columbus, Elkins Park, Fullerton, Houston, Memphis, New York, and Palo Alto, United StatesSee the 13 sites
Trial code
Status
Recruiting
Phase
Phase 3
People taking part
664 people, planned
Started
27 May 2026
Expected to end
15 May 2028
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Atropine Sulfate 0.05% Oph Soln
  • Placebo
Record updated
21 September 2026

Who can take part

Age
6 years to 11 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Refractive Error (cycloplegic autorefraction, spherical equivalent, at least one eye, inclusive) 6 years: -0.74 D to +0.75 D 7 and 8 years: -0.74 D to +0.50 D 9 and 10 years: -0.74 D to +0.25 D 11 years: -0.74 D to plano
  • Neither eye has -0.75 D or more myopia, spherical component
  • Anisometropia: Less than 1.50 D difference between OD and OS, cycloplegic autorefraction, spherical equivalent
  • Astigmatism: Less than 1.50 DC in both eyes by cycloplegic autorefraction
  • Successfully complete run-in period: take at least 90% of unit dose artificial tears for 2 to 4 weeks (# of unit-dose vials used divided by # nights since baseline visit must equal 0.90 or greater)

Who cannot take part

  • Ocular surgery (e.g., cataracts, strabismus)
  • Any previous myopia prevention/control therapy (e.g., atropine, soft contact lenses, orthokeratology, myopia control spectacles, etc.) for more than one month
  • Known allergy to atropine
  • Systemic issues that may affect accommodation or convergence (e.g., multiple sclerosis, myasthenia gravis, Graves ophthalmopathy, diabetes mellitus, Parkinson's disease, Down syndrome, etc.)
  • Ocular disease (e.g., congenital glaucoma, retinal disease, nystagmus, amblyopia, etc.)
  • If Visit 2 (randomization visit) is not completed within 4 weeks of the baseline, eligibility visit
  • Presence of strabismus (intermittent or constant) based on unilateral cover test at distance and near
  • Pregnancy by self-report

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 6 and 11 years old?

Where in United States

  • University of California, Berkeley, School of OptometryBerkeley, United StatesContact: Yoofi MensahTaking people
  • University of Alabama School of OptometryBirmingham, United StatesContact: Sindhu GurralaTaking people
  • Indiana UniversityBloomington, United StatesContact: Amy Peterson, ODTaking people
  • New England College of OptometryBoston, United StatesContact: Tamara KhanjyanTaking people
  • Illinois College of OptometryChicago, United StatesContact: Jessica MartinezTaking people
  • Case Western Reserve Department of OphthalmologyCleveland, United StatesContact: Adam J Peiffer, ODNot yet recruiting
  • The Ohio State University College of OptometryColumbus, United StatesContact: Alexis KostonTaking people
  • Pennsylvania College of Optometry at Drexel UniversityElkins Park, United StatesContact: Asami KojimaTaking people
  • Southern California College of Optometry at Marshall B. Ketchum UniversityFullerton, United StatesContact: Susan ParkerTaking people
  • University of Houston College of OptometryHouston, United StatesContact: Onose OkoegualeTaking people
  • Southern College of OptometryMemphis, United StatesContact: Elaine TurcotteTaking people
  • State University of New York College of OptometryNew York, United StatesContact: Keyana HunteTaking people
  • Stanford UniversityPalo Alto, United StatesContact: Joellen LeonardTaking people

About the trial

What the trial wants to find out

The aims of this clinical trial will test whether or not the onset of nearsightedness is delayed in a group of children randomized to nightly drops in 0.05% atropine in both eyes, in comparison to children who receiving nightly placebo drops in both eyes. The primary outcome is the two-year cumulative incidence of nearsightedness. The second aim of this project will determine whether atropine is associated with slower eye growth in children receiving nightly drops of atropine versus placebo.

The 2 groups in the trial

  • 0.05% AtropineTreatment being tested

    0.05% atropine instilled in each eye nightly at bedtime

    Treatment: Atropine Sulfate 0.05% Oph Soln

  • PlaceboPlacebo, for comparison

    Placebo drops instilled in each eye nightly at bedtime

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Fit questions
Built from NCT07567040, who can take part
Record updated
21 September 2026